Sanofi (ENXTPA:SAN) Expands Regeneron Alliance, Is The Stock Undervalued?

Alliance expansion puts Sanofi in focus

Sanofi (ENXTPA:SAN) is back on investor radars after extending its long-running antibody partnership with Regeneron and resolving an EU antitrust probe that had raised questions around its flu vaccine communications.

The refreshed alliance covers four new long acting antibody programs targeting type 2 inflammation, anchored by a €1b upfront payment to Regeneron and up to €7b in potential milestones. Future profits will be shared equally worldwide.

At a share price of €71.82, Sanofi has seen its 30 day share price return fall 4.8% and its year to date share price return decline 12.8%, while the 1 year total shareholder return is down 10%. Recent momentum looks weak despite this alliance news and the cleared antitrust overhang.

Spot opportunities around Sanofi's latest alliance shift by comparing it with a curated group of 188 high quality undervalued stocks that share solid fundamentals and more compressed valuations.

The Regeneron deal and cleared EU probe sit against a share price that has moved the other way. Is this Sanofi’s business being misread, or is sentiment finally catching up with the fundamentals that investors see on screen?

Most Popular Narrative: 60% Undervalued

On the narrative view, Sanofi’s fair value of €72.23 sits just above the latest close at €71.82, yet the author frames that small gap as part of a much wider disconnect between price and long term potential.

Der französische Pharmariese Sanofi bietet Anlegern derzeit eine interessante Kombination aus attraktiver Bewertung, starker Dividendenrendite und solider operativer Dynamik.

Wer jedoch ein substanzstarkes, krisenresistentes Unternehmen mit hohen Cashflows und einer starken Dividende sucht, findet in Sanofi derzeit einen attraktiven und fair bewerteten Titel.

See why 5 investors see Sanofi as 1% undervalued.

Result: Fair Value of €72.23 (UNDERVALUED)

Still, Sanofi’s reliance on key therapies and exposure to patent expiries, together with any setback in its broader pipeline, could easily puncture this undervalued storyline.

Find out about the key risks to this Sanofi narrative.

Next Steps

If this mix of optimism and caution around Sanofi feels conflicted, that is the point. It is why you should interrogate the numbers and sentiment yourself using the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Sanofi?

Do not stop your research with Sanofi. Broaden your watchlist with a few focused stock ideas filtered by quality, income potential and resilience.

• Pinpoint potential bargains by scanning a curated 188 high quality undervalued stocks that combine solid fundamentals with prices that have not fully reflected those qualities yet.
• Strengthen your income stream by focusing on companies in the 217 dividend fortresses that offer higher yields with an eye on payout sustainability.
• Reduce portfolio stress by concentrating on businesses in the 224 resilient stocks with low risk scores that show more resilient financial profiles across key checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com